CoChat

Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials

Open access
Facchinetti, Fabio, Orrù, Beatrice, Grandi, Giovanni, Unfer, Vittorio · 2019 · Gynecological Endocrinology

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Metformin (MET), the most commonly used insulin sensitizer, is the reference off-label drug for the treatment of polycystic ovary syndrome (PCOS), worldwide. However, its use may be limited mainly by gastrointestinal adverse effects. Myo-inositol (MI), a well-recognized food supplement, also represents an evidence-based treatment for PCOS women, popular in many countries. Our aim is to provide a systematic review of the literature and a meta-analysis which compares these two treatments, for their short-term efficacy and safety in PCOS patients. Systematic review and meta-analysis of randomized clinical trials (RCTs). RCTs were identified from 1994 through 2017 using MEDLINE, Cochrane Library, PubMed, and ResearchGate. Included studies were limited to those one directly comparing MET to MI on several hormones changes. Standardized mean difference (SMD) or risk ratios (RRs) with 95% CIs were calculated. Changes in fasting insulin was the main outcome of measure. Six trials with a total of 355 patients were included. At the end of treatment, no difference between MET and MI was found on fasting insulin (SMD=0.08 µU/ml, 95% CI: -0.31-0.46, p=.697), HOMA index (SMD =0.17, 95% CI: -0.53-0.88, p=.635), testosterone (SMD= -0.01, 95% CI: -0.24-0.21, p=.922), SHBG levels (SMD= -0.50 nmol/l, 95% CI: -1.39-0.38, p=.263) and body mass index (BMI) (SMD= -0.22, 95% CI: -0.60-0.16, p=.265). There was strong evidence of an increased risk of adverse events among women receiving MET compared to those receiving MI (RR =5.17, 95% CI: 2.91-9.17, p<.001). No differences were found in the effect of MET and MI on short-term hormone changes. The better tolerability of MI makes it more acceptable for the recovery of androgenic and metabolic profile in PCOS women.

Overview

Integrity signals

Registry

Crossref · 10.1080/09513590.2018.1540578

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 46 references

Research works printed but not linked: 2

  1. 10.1093/humrep/deh098 · DOI · Paper page
  2. Nehra J , Kaushal J , Singhal SR , et al. A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. Int J Pharm Sci Res. 2017;8:1664.

Cited by

See all 94

Metadata

Authors
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V.
Affiliations
  • University of Modena and Reggio Emilia (IT)
  • Lo.Li. Pharma S.r.l. (Italy) (IT)
  • Sapienza University of Rome (IT)
Corresponding author
Facchinetti, Fabio
Venue
Gynecological Endocrinology
Published
2019-01-07
Volume
35
Issue
3
Pages
198-206
ISSN
  • 0951-3590 (ISSN-L)
  • 1473-0766
OpenAlex
W2910430746
Cited by
94
References
46
Citations by year
2026: 6 · 2025: 8 · 2024: 10 · 2023: 18 · 2022: 15 · 2021: 12 · 2020: 18 · 2019: 7
FWCI
1.83
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Gynecological Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
metformin, myo-inositol, polycystic ovary syndrome, insulin sensitizers, fasting insulin, HOMA index, testosterone, sex hormone-binding globulin, body mass index, adverse events, tolerability, metabolic profile, short-term treatment efficacy, women's health, dietary supplements, gastrointestinal adverse effects, insulin resistance, hyperandrogenism
MeSH terms
Female, Humans, Hypoglycemic Agents, Inositol, Metformin, Polycystic Ovary Syndrome, Randomized Controlled Trials as Topic, Treatment Outcome, Off-Label Use

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1080/09513590.2018.1540578
The paper
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019). Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecological Endocrinology. https://doi.org/10.1080/09513590.2018.1540578

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.